细胞外基质与乳腺癌耐药
Extracellular Matrix and Breast Cancer Resistance
DOI: 10.12677/ACM.2020.104103, PDF,   
作者: 王国徽, 卿 晨：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明
关键词: 细胞外基质；乳腺癌；耐药；Extracellular Matrix； Breast Cancer； Drug Resistance
摘要: 乳腺癌是女性癌症中发病率最高，危害最严重的肿瘤之一。乳腺癌治疗方式主要有手术、化疗、放疗、分子靶向和内分泌治疗。绝大多数患者治疗后产生的耐药，复发和转移是导致乳腺癌患者死亡的主要原因。以前对肿瘤耐药机制的研究局限于肿瘤细胞本身，以此发展的治疗方法所取得的成效并不理想。随着研究的不断深入，人们逐渐认识到细胞外基质在肿瘤耐药性的产生中也扮演着关键的角色。随着人们对细胞外基质(Extracellular Matrix, ECM)和其受体整合素(integrin, Int)的研究发现，ECM组成在癌症发展过程中持续变化，可能与化疗耐药有关。本文就细胞外基质与乳腺癌的耐药关系进行综述。
Abstract: Breast cancer is one of the tumors with the highest incidence and the most serious harm among female cancers. The main treatments for breast cancer are surgery, chemotherapy, radiotherapy, targeting and endocrine therapy. The drug resistance, recurrence and metastasis of the vast majority of patients after treatment are the main causes of death in patients with breast cancer. The previous research on the mechanism of tumor drug resistance is limited to the tumor cells themselves, and the results of the treatment methods developed by this method are not satisfactory. With the deepening of research, people gradually realize that extracellular matrix also plays a key role in the generation of tumor drug resistance. With the study of extracellular matrix (ECM) and its receptor integrin (Int), it has been found that the composition of ECM changes continuously during the development of cancer, which may be related to chemotherapy resistance. This article reviews the relationship between extracellular matrix and drug resistance of breast cancer.
文章引用：王国徽, 卿晨. 细胞外基质与乳腺癌耐药[J]. 临床医学进展, 2020, 10(4): 658-663. https://doi.org/10.12677/ACM.2020.104103

参考文献

[1] Jena, M.K. and Janjanam, J. (2018) Role of Extracellular Matrix in Breast Cancer Development: A Brief Update. F1000Research, 7, 274. [Google Scholar] [CrossRef] [PubMed]
[2] Oudin, M.J.W.V. (2016) Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harbor Symposia on Quantitative Biology, 81, 189-205. [Google Scholar] [CrossRef] [PubMed]
[3] Barcelloshoff, M.H. (2000) The Influence of the Microenvi-ronment on the Malignant Phenotype. Molecular Medicine Today, 6, 324-329. [Google Scholar] [CrossRef] 
[4] Beacham, D.A. and Cukierman, E. (2005) Stromagenesis: The Changing Face of Fibroblastic Microenvironments during Tumor Progression. Seminars in Cancer Biology, 15, 329-341. [Google Scholar] [CrossRef] [PubMed]
[5] Halper, J. and Kjaer, M. (2014) Basic Components of Connective Tissues and Extracellular Matrix: Elastin, Fibrillin, Fibulins, Fibrinogen, Fibronectin, Laminin, Tenascins and Thrombospondins. Advances in Experimental Medicine & Biology, 3, 31-47. [Google Scholar] [CrossRef] [PubMed]
[6] 马婕, 邱涵, 张倩, 徐正丰. VI型胶原蛋白在乳腺癌组织中的表达及临床意义[J]. 中国妇幼健康研究, 2016, 27(1): 303-304.
[7] 王玉珍, 段惠军, 陈建国, 呼亚伟, 李英敏. 层粘蛋白和Ⅳ型胶原在乳腺癌的表达[J]. 河北医科大学学报. 2001(2): 10-2+70.
[8] Insua-Rodríguez, J. and Oskarsson, T. (2015) The Extracellular Matrix in Breast Cancer. Advanced Drug Delivery Reviews, 97, 41-55. [Google Scholar] [CrossRef] [PubMed]
[9] Hansen, U. (2013) The Expanded Collagen VI Family: New Chains and New Questions. Connective Tissue Research, 54, 345-350.
[10] Faller, W.J., Rafferty, M., Hegarty, S., Gremel, G., Ryan, D., Fraga, M.F., et al. (2010) Metallothionein 1E Is Methylated in Malignant Melanoma and Increases Sensitivity to Cisplatin-Induced Apoptosis. Melanoma Research, 20, 392-400. [Google Scholar] [CrossRef] 
[11] Hanker, A.B., Estrada, M.V., Bianchini, G., Moore, P.D., Zhao, J., Cheng, F., et al. (2017) Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 77, 3280-3292. [Google Scholar] [CrossRef] 
[12] Valkenburg, K.C., de Groot, A.E. and Pienta, K.J. (2018) Targeting the Tumour Stroma to Improve Cancer Therapy. Nature Reviews Clinical Oncology, 15, 366-381. [Google Scholar] [CrossRef] [PubMed]
[13] Morais, C., Small, D.M., Vesey, D.A., Martin, J., Johnson, D.W. and Gobe, G.C. (2014) Fibronectin and Transforming Growth Factor Beta Contribute to Erythropoietin Resistance and Maladaptive Cardiac Hypertrophy. Biochemical and Biophysical Research Communications, 444, 332-337. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, K., Wu, F., Seo, B.R., Fischbach, C., Chen, W., Hsu, L., et al. (2017) Breast Cancer Cells Alter the Dynamics of Stromal Fibronectin-Collagen Interactions. Matrix Biology, 60-61, 86-95. [Google Scholar] [CrossRef] [PubMed]
[15] Amalia, A., Serena, M., Letizia, P., et al. (2016) Hepatic Stellate Cells Induce Hepatocellular Carcinoma Cell Resistance to Sorafenib through the Laminin-332/α3 Integrin Axis Recovery of Focal Adhesion Kinase Ubiquitination.
[16] Qiu, X., Tan, H.S., Fu, D.Y., et al. (2018) Laminin Is over Expressed in Breast Cancer and Facilitate Cancer Cell Metastasis.
[17] Nithikoon, A. and Pithi, C. (2019) Integrin as a Molecular Target for Anti-Cancer Approaches in Lung Cancer. Anticancer Research, 39, 541-548. [Google Scholar] [CrossRef] [PubMed]
[18] Seguin, L., Desgrosellier, J.S., Weis, S.M. and Cheresh, D.A. (2015) Integrins and Cancer: Regulators of Cancer Stemness, Metastasis, and Drug Resistance. Trends in Cell Biology, 25, 234-240. [Google Scholar] [CrossRef] [PubMed]
[19] Kechagia, J.Z., Ivaska, J. and Roca-Cusachs, P. (2019) Integrins as Biomechanical Sensors of the Microenvironment. Nature Reviews Molecular Cell Biology, 20, 457-473. [Google Scholar] [CrossRef] [PubMed]
[20] 温敏, 刘莹莹, 徐金锋, 孙瑜, 董发进, 苏莉莉, 郭凤娟. 乳腺癌肿瘤微环境相关治疗靶点的研究进展[J]. 广东医学, 2019, 40(7): 908-912.
[21] Yuan, J., Yang, L., Tu, G., Zhu, Q., Chen, M.S., Cheng, H., Luo, H.J., Fu, W.J., Li, Z.H. and Yang, G.L. (2015) Acquisition of Epithelial-Mesenchymal Transition Phenotype in the Tamoxifen-Resistant Breast Cancer Cell: A New Role for G Protein-Coupled Estrogen Receptor in Mediating Tamoxifen Resistance through Cancer-Associated Fibroblast-Derived Fibronectin and β1-Integrin Signaling Pathway in Tumor Cells. Breast Cancer Research, 17, 1-18. [Google Scholar] [CrossRef] [PubMed]
[22] Ren, X., Xu, J., Cooper, J.P., Kang, H. and Erdreich-Epstein, A. (2012) c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αvβ3 and αvβ5. PLoS ONE, 7, e42291. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, H.-Y., Pan, L., Yang, H.-L., Xia, P., Yu, W.-C., Tang, W.-Q., et al. (2018) Integrin α5β1 Suppresses rBMSCs Anoikis and Promotes Nitric Oxide Production. Biomedecine & Pharmacotherapie, 99, 1-8. [Google Scholar] [CrossRef] [PubMed]
[24] Miyata, K. and Takebe, J. (2013) Anodized-Hydrothermally Treated Titanium with a Nanotopographic Surface Structure Regulates Integrin-α6β4 and Laminin-5 Gene Expression in Adherent Murine Gingival Epithelial Cells. The Journal of Prosthodontic Research, 57, 99-108. [Google Scholar] [CrossRef] [PubMed]
[25] 王莹, 姜媛媛, 李国军, 王冰. 整合素在肿瘤发展中的作用[J]. 中国化工贸易, 2017, 9(20): 235.
[26] Danen, E. (2005) Integrins: Regulators of Tissue Function and Cancer Progres-sion. Current Pharmaceutical Design, 11, 881-891. [Google Scholar] [CrossRef] [PubMed]
[27] Campbell, P.S. (2019) AhR Ligand Aminoflavone Suppresses α6-Integrin-Src-Akt Signaling to Attenuate Tamoxifen Resistance in Breast Cancer Cells. Journal of Cellular Physiology, 234, 108-121. [Google Scholar] [CrossRef] [PubMed]
[28] Naci, D., Vuori, K. and Aoudjit, F. (2015) α2β1 Integrin in Cancer Development and Chemoresistance. Seminars in Cancer Biology, 35, 145-153. [Google Scholar] [CrossRef] [PubMed]
[29] Weaver, V.M., Lelièvre, S., Lakins, J.N., Chrenek, M.A. and Bissell, M.J. (2002) Beta4 Integrin-Dependent Formation of Polarized Three-Dimensional Architecture Confers Resistance to Apoptosis in Normal and Malignant Mammary Epithelium. Cancer Cell, 2, 205-216. [Google Scholar] [CrossRef] 
[30] Stupack, D.G. (2001) Apoptosis of Adherent Cells by Re-cruitment of Caspase-8 to Unligated Integrins. Journal of Cell Biology, 155, 459-470. [Google Scholar] [CrossRef] [PubMed]

为你推荐